caa a22 4500 465789943 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00198601 doi (NATIONALLICENCE)springer-10.1007/BF00198601 Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors [Elektronische Daten] A Pediatric Oncology Group phase II study [R. Castleberry, A. Ragab, C. Steuber, B. Kamen, S. Toledano, K. Starling, D. Norris, P. Burger, J. Krischer] Summary: To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various noncentral nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses. Kluwer Academic Publishers, 1990 brain tumors nationallicence solid tumors nationallicence childhood nationallicence AZQ nationallicence recurrent tumors nationallicence phase II study nationallicence Castleberry R. The Departments of Pediatrics of the University of Alabama at Birmingham, USA aut Ragab A. Emory University, USA aut Steuber C. Baylor University, USA aut Kamen B. University of Texas Southwestern Medical School, USA aut Toledano S. University of Miami, USA aut Starling K. West Virginia University, USA aut Norris D. The Cleveland Clinics, USA aut Burger P. Duke University Medical Center, USA aut Krischer J. The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA aut Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 401-406 0167-6997 8:4<401 1990 8 10637 https://doi.org/10.1007/BF00198601 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00198601 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Castleberry R. The Departments of Pediatrics of the University of Alabama at Birmingham, USA aut NATIONALLICENCE 700 1- Ragab A. Emory University, USA aut NATIONALLICENCE 700 1- Steuber C. Baylor University, USA aut NATIONALLICENCE 700 1- Kamen B. University of Texas Southwestern Medical School, USA aut NATIONALLICENCE 700 1- Toledano S. University of Miami, USA aut NATIONALLICENCE 700 1- Starling K. West Virginia University, USA aut NATIONALLICENCE 700 1- Norris D. The Cleveland Clinics, USA aut NATIONALLICENCE 700 1- Burger P. Duke University Medical Center, USA aut NATIONALLICENCE 700 1- Krischer J. The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 401-406 0167-6997 8:4<401 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer